CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 472 enrolled
Drug / intervention
Amoxicillin/clavulanate +1 moredrug
Likely dose
Amoxicillin/clavulanate 1 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02141217
NCT02141217Phase 4Completed

Efficacy, Safety and Tolerability of Amoxicillin + Clavulanic Acid (875mg/125mg) Two Times a Day Compared to Clindamycin (150mg) Four Times a Day for 5-7 Days in Treatment of Acute Odontogenic Infection With or Without Abscess

GlaxoSmithKline·interventional·Posted May 19, 2014·Updated Sep 25, 2017

In Brief

A Phase 4 clinical trial evaluating Amoxicillin/clavulanate and Clindamycin for Focal Infection, Dental. Completed, enrolled 472 participants across 15 sites in 4 countries.

Detailed Summary

In clinical practice, amoxicillin + clavulanic acid is widely used in the treatment of odontogenic infection. Therefore, this study is designed to generate data to support its use by demonstrating efficacy, safety and tolerability in comparison with clindamycin in subjects with acute odontogenic infections with or without abscess. This will be a two-arm, parallel, comparative, observer blind, randomised study to assess efficacy, safety and tolerability of amoxicillin + clavulanic acid (875mg/125mg) in comparison with clindamycin (150mg) administered for 5-7 days in subjects with acute odontogenic infections with or without abscess. The study will be performed in adult subjects both male and female ≥18 years of age who present with acute odontogenic infections. A total of 472 subjects will be randomized in 1:1 ratio, i.e. 236 subjects in each treatment arm. The treatment duration of the study will be at least 5 days or maximum 7 days depending upon the treatment response. Subjects will be assessed on Day 5 and if Investigator feels the need of continuing the treatment at Day 5 then treatment will be continued till Day 7. For subjects who do not show treatment response on Day 5, assessments will be performed on Day 7.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesMalaysia, Philippines, Thailand, Vietnam
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 19, 2014
Enrollment StartMar 21, 2013
Primary CompletionDec 28, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.1 years ago

Interventions

Amoxicillin/clavulanatedrug

Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.

Clindamycindrug

Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.